Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
|Slideshows|August 8, 2022
August 8 is National CBD Day 2022
Author(s)Psychiatric Times Editors
In honor of National CBD Day, Psychiatric Times™ shares some recent expert discussions on the pros, cons, and clinical implications of cannabis use in psychiatry.
Advertisement
Advertisement
Related to this article
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.
New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
New Adult ADHD Guidelines: What Resources Are Coming Soon
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5